CEO SUMMARY: Unilab’s desire to purchase $60 million Bio-Cypher must be viewed against the impending acquisition by Quest Diagnostics of SmithKline Beecham Clinical Laboratories (SBCL). Whenever Quest takes control of SBCL’s lab operations, it automatically becomes a significant competitor to Unilab in the Golden State. For Unilab, acquiring Bio-Cypher represents both an offensive and defensive […]
To access this post, you must purchase The Dark Report.